Abstract
Erythropoietin (EPO) is a hypoxia-inducible hormone best known for its role in erythropoiesis. However, EPO also has anti-inflammatory and tissue-protective characteristics in multiple organs as summarised in this review. In the brain, EPO is upregulated by hypoxia, regulates ventilation and plays a key role in neuroprotection and neuroplasticity. Systemically administered EPO crosses the blood-brain-barrier, enhances neuroplasticity and improves cognitive functions in several disorders of the brain. Given this evidence, a trial is being planned to investigate whether EPO can improve the physiologic and neurologic outcome of COVID-19.
| Translated title of the contribution | Erythropoietin as possible treatment of brain diseases |
|---|---|
| Original language | Danish |
| Journal | Ugeskrift for Laeger |
| Volume | 182 |
| Issue number | 44 |
| ISSN | 0041-5782 |
| Publication status | Published - 26 Oct 2020 |